Dravet Syndrome Market 2023 – Global Trends, Competitive Landscape, Key Insights and Top Player Overview with Forecast Analysis

MarketReportsOnline.com adds "Global Dravet Syndrome Market: Industry Analysis & Outlook (2019-2023)" report to its research store. Key major players are Zogenix, Zynerba, GW Pharmaceuticals, and OPKO. Currently, only GW Pharmaceuticals.

Pune, India - February 4, 2019 /MarketersMedia/ —

Dravet syndrome, formerly known as severe myoclonic epilepsy of infancy (SMEI), is a severe kind of epilepsy which causes seizures. High fever is usually a trigger for these seizures. It is a rare disorder that affects an estimated 1 in every 20,000–40,000 births. It usually develops in the six month of age. It is caused by loss-of-function mutations in one copy of the SCN1A gene. Patients with Dravet syndrome are not able to produce sufficient levels of functional Nav1.1 sodium channel, preventing inhibitory neurons from firing properly.

The disorder is considered orphan indication. And there are very limited treatment options available in the market. However, several therapeutics for Dravet syndrome are in pipeline.

Complete report on Global Dravet Syndrome Market spread across 62 pages with providing 4 company profiles, 3 tables and 30 charts is now available at http://www.marketreportsonline.com/782423.html.

The drugs in development are getting orphan drug designation by FDA and EMA. The Dravet syndrome market in Europe and the U.S. is likely to exhibit significant growth in the next five years due to increasing research and development activities conducted by several companies. Several companies are making alliances for developing therapeutics for Dravet syndrome. Currently, the U.S and Europe are holding the potential growth for Dravet Syndrome market due to increasing R&D into new drug development for Dravet syndrome and approval for these drugs in these regions.

Key players of the market include Zogenix, Zynerba, GW Pharmaceuticals, and OPKO. Currently, only GW Pharmaceuticals’ Epidiolex is commercially available. Other players are currently developing their drugs or seeking for commercial approval by FDA and EMA. Zogenix’s ZX008 is expected to penetrate market in 2019 and create competition for GW Pharmaceuticals. Currently, the market is dominated by generic drugs.

Order a copy of this “Global Dravet Syndrome Market” report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=782423.

Major Points from Table of Contents Provided in Global Dravet Syndrome Market Report 2019-2023:

1. Overview
1.1 Dravet Syndrome

2. Global Dravet Syndrome Drug Market
2.1 ZX008 Sales Value Forecast
2.2 Epidiolex Sales Value Forecast

3. Regional Dravet Syndrome Drug Market
3.1 The U.S.
3.2 Europe

4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends
4.3 Challenges

5. Competition
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
5.1.3 Comparison of Epidiolex and ZX008

6. Company Profiles

Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html.

Contact Info:
Name: vishal Kalra
Email: Send Email
Organization: MarketReportsOnline
Phone: + 1 888 391 5441
Website: http://www.marketreportsonline.com/782423.html

Source URL: https://marketersmedia.com/dravet-syndrome-market-2023-global-trends-competitive-landscape-key-insights-and-top-player-overview-with-forecast-analysis/478459

Source: MarketersMedia

Release ID: 478459